Corresponding Author: Manish M. Patel, MD, COVID-19 Response Team, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS H-24-7, Atlanta, GA 30333 (firstname.lastname@example.org).
Published Online: October 16, 2020. doi:10.1001/jama.2020.19328
Conflict of Interest Disclosures: Dr Ferdinands reported receiving nonfinancial support from the Institute for Influenza Epidemiology outside the submitted work. No other disclosures were reported.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
H , Feng
S , Lewnard
et al. The use of test-negative controls to monitor vaccine effectiveness. Epidemiology
. 2020;31(1):43-64.PubMedGoogle ScholarCrossref
MM , Glass
R , Desai
et al. Fulfilling the promise of rotavirus vaccines: how far have we come since licensure? Lancet Infect Dis
. 2012;12(7):561-570.PubMedGoogle ScholarCrossref
J , Brenner
R , Rao
et al. Evaluating new vaccines for developing countries: efficacy or effectiveness? JAMA
. 1996;275(5):390-397.PubMedGoogle ScholarCrossref
ML , Rothman
KJ . Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness. Vaccine
. 2015;33(11):1313-1316.PubMedGoogle ScholarCrossref
WJ , Rhodes
A , Cheng
AC , Peacock
SJ , Prescott
HC . Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). JAMA
. 2020;324(8):782-793.PubMedGoogle ScholarCrossref
Generic Protocol for Monitoring Impact of Rotavirus Vaccination on Rotavirus Disease Burden and Viral Strains. World Health Organization; 2009.